Relationship between serum phosphate and mortality in critically ill children receiving continuous renal replacement therapy

被引:2
|
作者
Zhou, Xiong [1 ]
He, Jie [1 ]
Zhu, Desheng [1 ]
Yao, Zhenya [1 ]
Peng, Dan [1 ]
Zhang, Xinping [1 ]
机构
[1] Hunan Childrens Hosp, Pediat Dept Crit Care Med, Changsha, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2023年 / 11卷
关键词
continuous renal replacement therapy; children; phosphate; mortality; pediatric intensive care unit; GROWTH-FACTOR; 23; OUTCOMES; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA;
D O I
10.3389/fped.2023.1129156
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
PurposeWe aimed to explore the relationship between serum phosphate concentration and 90-day mortality in critically ill children receiving continuous renal replacement therapy (CRRT).MethodsData from the medical records of children aged <13 years who received CRRT at the Pediatric Intensive Care Unit of Hunan Children's Hospital, China from January 2015 to June 2020 were retrospectively collected. Children were grouped into four categories according to the baseline phosphate concentration before CRRT and mean serum phosphate concentration during CRRT: <0.81 mmol/L (hypophosphatemia), 0.81-1.19 mmol/L, 1.2-2.4 mmol/L (normal phosphate concentration), and >2.4 mmol/L (hyperphosphatemia), with the normal phosphate group serving as the comparator group. The correlation of the serum phosphate concentration before and during CRRT with the 90-day mortality after CRRT initiation was analyzed using logistic regression.ResultsA total of 177 children were included in our study. The mean serum phosphate concentration before CRRT was 1.46 mmol/L (quartiles: 1.04, 2.20). The 90-day mortality rate was increased in children with a serum phosphate concentration >2.4 mmol/L before CRRT (adjusted odds ratio [aOR] 3.74, 95% confidence interval [CI] 1.42-9.86, P = 0.008). The mean serum phosphate concentration during CRRT was 1.2 mmol/L (quartiles: 0.91, 1.49). The 90-day mortality rate was increased in children with a mean serum phosphate concentration >2.4 mmol/L during CRRT (aOR 7.34, 95% CI 1.59-33.88, P = 0.011).ConclusionHyperphosphatemia before and during CRRT predicts a higher 90-day mortality rate.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy
    Trotman, RL
    Williamson, JC
    Shoemaker, DM
    Salzer, WL
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (08) : 1159 - 1166
  • [32] CARBAPENEM DOSING RECOMMENDATIONS IN CRITICALLY ILL PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY
    Chaijamorn, Weerachai
    So-Ngern, Apichot
    Charoensareerat, Taniya
    Srisawat, Nattachai
    Pasee, Ploynapat
    Kaewkum, Nuttabodin
    Jintasataporn, Kanwara
    NEPHROLOGY, 2019, 24 : 39 - 39
  • [33] Association of continuous kidney replacement therapy timing and mortality in critically ill children
    Banigan, Maureen A.
    Keim, Garrett
    Traynor, Danielle
    Yehya, Nadir
    Lindell, Robert B.
    Fitzgerald, Julie C.
    PEDIATRIC NEPHROLOGY, 2024, 39 (07) : 2217 - 2226
  • [34] Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy
    Thy, Michael
    Urien, Saik
    Foissac, Frantz
    Bouazza, Naim
    Gana, Ines
    Bille, Emmanuelle
    Beranger, Agathe
    Toubiana, Julie
    Berthaud, Romain
    Lesage, Fabrice
    Renolleau, Sylvain
    Treluyer, Jean-Marc
    Benaboud, Sihem
    Oualha, Mehdi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (12)
  • [35] Meropenem population pharmacokinetics and dosing regimen optimization in critically ill children receiving continuous renal replacement therapy
    Thy, M.
    Urien, S.
    Bouazza, N.
    Foissac, F.
    Bille, E.
    Rapp, M.
    Beranger, A.
    Lui, G.
    Lesage, F.
    Renolleau, S.
    Treluyer, J. M.
    Oualha, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 92 - 93
  • [36] Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy
    Michael Thy
    Saik Urien
    Naim Bouazza
    Frantz Foissac
    Inès Gana
    Emmanuelle Bille
    Agathe Béranger
    Julie Toubiana
    Romain Berthaud
    Fabrice Lesage
    Sylvain Renolleau
    Jean-Marc Tréluyer
    Sihem Benaboud
    Mehdi Oualha
    Clinical Pharmacokinetics, 2022, 61 : 1609 - 1621
  • [37] Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children receiving continuous renal replacement therapy
    Thy, M.
    Urien, S.
    Foissac, F.
    Bouazza, N.
    Bille, E.
    Beranger, A.
    Rapp, M.
    Lui, G.
    Lesage, F.
    Renolleau, S.
    Treluyer, J. M.
    Oualha, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 76 - 76
  • [38] Continuous renal replacement therapy in critically ill neonates
    S Rödi
    G Zobel
    B Urlesberger
    E Ring
    M Kuttnig-Haim
    Critical Care, 2 (Suppl 1):
  • [39] Continuous renal replacement therapy in the critically ill patient
    Mehta, RL
    KIDNEY INTERNATIONAL, 2005, 67 (02) : 781 - 795
  • [40] Continuous renal replacement therapy for the critically ill patient
    Dessain, Tessa E.
    Martin, Daniel
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2018, 79 (01) : C2 - C7